

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the approximate reduction in risk of death for patients receiving ivosidenib compared to placebo for advanced cholangiocarcinoma with an IDH1 mutation in the final overall survival analysis of the Phase III ClarIDHy trial?**
 - a. 10%
 - b. 20%**
 - c. 30%
 - d. Trend toward overall survival benefit
 - e. No significant overall survival benefit
- 2. The bispecific antibody zanidatamab binds to which of the following targets?**
 - a. HER2 and CD8
 - b. HER2 and HER3
 - c. HER2 and FGFR2
 - d. Two distinct HER2 domains**
- 3. The ongoing Phase III HERIZON-BTC-302 trial is evaluating zanidatamab with standard therapy versus standard therapy alone for patients with HER2-positive biliary tract cancer (BTC) in which of the following settings?**
 - a. As adjuvant therapy for BTC after surgical resection or ablation
 - b. As first-line therapy for advanced or metastatic BTC**
 - c. As second-line therapy for advanced or metastatic BTC
 - d. As salvage therapy for advanced or metastatic BTC
- 4. The ongoing Phase III DESTINY-BTC01 study is comparing trastuzumab deruxtecan alone or in combination with which of the following agents to standard treatment as first-line therapy for patients with advanced HER2-expressing BTC?**
 - a. T-DM1
 - b. Trastuzumab/pertuzumab
 - c. Rilvegostomig**
 - d. Zanidatamab
- 5. The bispecific antibody rilvegostomig binds to which of the following targets?**
 - a. HER2 and CD8
 - b. HER2 and HER3
 - c. PD-1 and TROP2
 - d. PD-1 and TIGIT**